Myelin and disorders that affect the formation and maintenance of this sheath

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 6, Issue 1, 2000, Pages 47-58

  Porter, Brenda E ^a,b   Tennekoon, Gihan ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOLEUKODYSTROPHY; ARTICLE; CANAVAN DISEASE; DEMYELINATING DISEASE; GLOBOID CELL LEUKODYSTROPHY; HEREDITARY MOTOR SENSORY NEUROPATHY; METACHROMATIC LEUKODYSTROPHY; MOLECULAR GENETICS; MULTIPLE SCLEROSIS; MYELIN SHEATH; PELIZAEUS MERZBACHER DISEASE; PRIORITY JOURNAL;

ANIMALS; DEMYELINATING DISEASES; GROWTH; HUMANS; MYELIN PROTEINS; MYELIN SHEATH; NEURODEGENERATIVE DISEASES; OLIGODENDROGLIA; SCHWANN CELLS;

EID: 0034052604     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2779(2000)6:1<47::AID-MRDD7>3.0.CO;2-M     Document Type: Article

References (145)

1. Adachi M, Schenk L, Cazara J, et al. 1973. Spongy degeneration of the central nervous system (van Bogaert and Bogaert-Bertrand disease). Hum Pathol 4:331-346.
2. Adornato BT, O'Brien JS, Lampert PW, et al. 1972. Cerebral spongy degeneration of infancy: a biochemical and ultrastructural study of affected twins. Neurology 22:202-210.
3. Auborg P, Adansbaum C, Lavallard-Rousseau M, et al. 1993. A two year trial of oleic and erucic acids (Lorenzo's oil) as treatment for adrenomyeloneuropathy. N Engl J Med 329:745-752.
4. Auborg P, Blanche S, Jambaque I, et al. 1990. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Mod 322:1860-1866.
5. Austin JH. 1957. Metachromatic form of diffuse cerebral sclerosis. I. Diagnosis during life by urine sediment examination. Neurology 7:415-426.
6. Austin JH, Lehfeldt D. 1965. Studies in Globoid (Krabbe) leukodystrophy. III. Significance of experimentally-produced globoid-like elements in rat white matter and spleen. J Neuropathol Exp Neurol 24:265-289.
7. Aydinli N, Caliskan M, Ozmen M, et al. 1998. Neuroradiologic aspects of West syndrome. Pediatric Neuroradiologist 19:211-216.
8. Barker PB, Bryan RN, Kumar AJ, et al. 1992. Proton NMR spectroscopy of Canavan's disease. Neuropediatr 23:263-267.
9. Barkovich JA, Lyon G, Evrard P. 1992. Formation, maturation and disorders of white matter. AJNR Am J Neuroradiology 13:447-461.
10. Barres B, Raff M. 1993. Proliferation oligodendrocyte precursors depend on electrical activity in axons. Nature 361:258-260.
11. Barres B, Schmid R, Sendtner M, et al. 1993a. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 118:283-295.
12. Barres B, Jacobson M, Schmid R, et al. 1993b. Does oligodendrocyte survival depend on axons? Curr Biol 3:489-497.
13. Barres B, Lazar M, Raff M. 1994. A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development. Development 120:1097-1108.
14. Barres B, Raff M. 1996. Axonal control of oligodendrocyte development. In: Jessen K, Richardson W, editors. Glial cell development. Bios Scientific Publishers, p 71-84.
15. Becker LE. 1992. Lysosomes, peroxisomes and mitochondria: function and disorder. AJNR Am J Neuroradiology 13:609-620.
16. Berger J, Molzer B, Fae I. 1994. X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes. Biochem Biophys Res Commun 205:1638-1643.
17. Berger J, Loschl B, Bernheimer H, et al. 1997. Occurrence, distribution and phenotype of arylsulfatase A mutations in patients with metachromatic leukodystrophy. Am J Med Gen 69:335-334.
18. Boulloche J, Aicardi J. 1986. Pelizaeus-Merzbacher disease: clinical and nosological study. J Child Neur 1:233-239.
19. Bruzzone R, White T, Paul D. 1996. Connections with connexinst: the molecular basis of direct intercellular signalling. Eur J Biochem 238:1-27.
20. Campagnoni A. 1988. Molecular biology of myelin proteins. J Neurochem 51:1-14.
21. Campagnoni A, Macklin W. 1988. Cellular and molecular aspects of myelin protein gene expression. Mol Neurobiol 2:41-89.
22. Canavan MM. 1931. Schilder's encephalitis periaxilis diffusa. Arch Neurol Psychiatry 25:299-308.
23. Caro PA, Marks HG. 1990. Magnetic resonance imaging and computed tomography in Pelizaeus-Merzbacher disease. Magn Reson Imaging 8:791-796.
24. Carson J, Nielson M, Barbarese E. 1983. Developmental expression of myelin basic protein in mouse brain. Dev Biol 96:485-492.
25. Chu AB, Sever JL, Madden DL, et al. 1983. Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseases. Ann Neurol 13: 434-439.
26. Cioni G, Bartalena L, Biagioni E, et al. 1992. Neuroimaging and functional outcome of neonatal leukomalacia. Behav Brain Res 49: 7-19.
27. Cole GF, Stuart CA. 1995. A long perspective on childhood multiple sclerosis. Dev Med Child Neurol 37:661-666.
28. Davis J, Lambert S, Bennett V. 1996. Molecular composition of the node of Ranvier. J Cell Biol 135:1355-1367.
29. De Gasperi R, Gama Sosa MA, Sartorato EL, et al. 1996. Molecular heterogeneity of late-onset forms of globoid-cell leukodystrophy. Am J Hum Genet 59:1233-1242.
30. Duquette P, Murray TJ, Pleines J, et al. 1987. Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr 111:359-363.
31. Einheber S, Zanassi G, Ching W, et al. 1997. The axonal membrane caspr, a homologue of neurexin IV, is a component of the septate like paranodal junctions that assemble during myelmation. J Cell Biol 139:1495-1506.
32. Ellis D, Malcolm S. 1994. Proteolipid protein gene dosage effect in Pelizaeus-Merzbacher disease. Nature Genet 6:333-334.
33. Engelbrecht V, Rassek M, Gartner J, et al. 1997. The value of new MRI techniques in adrenoleukodystrophy. Pediatr Radiol 27:207-215.
34. Fannon A, Sherman D, Ilyinaq-Gragerova G, et al. 1995. Novel E-Cadherin-mediated adhesion in peripheral nerve. J Cell Biol 129:189-202.
35. Fletcher JM, Bohan TP, Brandt ME, et al. 1992. Cerebral white matter and cognition in hydrocephalic children. Arch Neurol 49:818-824.
36. Fujii Y, Konishi M, Maeda M, et al. 1993. MRI assessment of myelination patterns in high-nsk infants. Pediatr Neurol 9:194-197.
37. Garbern JY, Cambi F, Tang X-M, et al. 1997. Proteolipid protein is necessary in peripheral as well as central myelin. Neuron 19:205-218.
38. Geiselmann V. 1991. An assay tor the rapid detection of the arylsulfatase A pseudodeficiency allele facilitates diagnosis and genetic counseling for metachromatic leukodystrophy. Hum Genet 86:251-255.
39. Ghezzi A, Deplano V, Faroni J, et al. 1997. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler 3:43-46.
40. Gieselmann B, Polten A, Kreysing J, et al. 1989. Arylsulfatase A pseudodeficiency: loss of a N-glycosylation site and a polyadenylation signal. Proc Natl Acad Sci USA 86:36-40.
41. Gitten J, Dede D, Fennell E, et al. 1998. Neurobehavioral development in joubert syndrome. J Child Neurol 13:391-397.
42. Goldstein FB. 1969. The enzymatic synthesis of N-acetyl-L-aspartic acid by subcellular preparations of rat brain. J Biol Chem 244:4257-4260.
43. Gould R, Jessen K, Mirsky R, et al. 1992. The cell of Schwann. In: Martenson R, editor. Myelin: biology and chemistry. CRC Press p 123-171.
44. Gow A, Lazzarini RA. 1996. The cellular mechanism governing the severity of Pelizaeus-Merzbacher disease. Nat Genet 13:422-428.
45. Gow A, Southwood CM, Lazzarini RA. 1998. Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease. J Cell Bio 140:925-934.
46. Griffin DE, Moser HW, Mendoza Q, et al. 1985. Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Ann Neurol 18:660-664.
47. Griffin I. 1996. Myelin mutants: model system tor the study of normal and abnormal myelination. BioEssays 18:789-797.
48. Grodd W. 1993. Normal and abnormal patterns of myelin development of the fetal and infantile human brain using magnetic resonance imaging. Curr Opin Neurol Neurosurg 6:393-397.
49. Gustavson K, Hagberg B. 1971. The incidence and genetics of metachromatic leukodystrophy in northern Sweden. Acta Pediatr Scand 60:585-590.
50. Hagberg B, Kolberg H, Sourander P, et al. 1970. Infantile globoid cell leukodystrophy (Krabbe's disease): a clinical and genetic study of 32 Swedish cases 1953-1967. Neuropaditrie 1:74-88.
51. Hageman AT, Gabreels FJ, de Jong JG, et al. 1995. Clinical symptoms ot adult metachromatic leukodystrophy and arylsulfatase A pseudodeficiency. Arch Neurol 52:408-413.
52. Hanefeld FA. 1994. Characteristics of childhood multiple sclerosis. Int MSJ 1:91-97.
53. Hanlo PW, Gooskens RJ, van Schooneveld M, et al. 1997. The effect of intracranial pressure on myelination and the relationship with neurodevelopment in infantile hydrocephalus. Dev Med Child Neurol 39:286-291.
54. Hassink RI, Hiltbrunner B, Muller S, et al. 1992. Assessment of brain maturation by T2-weighted MRI. Neuropediatr 23:72-74.
55. Heim P, Claussen M, Hoffmann B, et al. 1997. Leukodystrophy incidence in Germany. Am J Med Gen 71:475-478.
56. Hettema EH, van Roermaund CWT, Distel B, et al. 1996. The ABC transporter proteins Pat1 and Pat2 are required for import of long-chain tatty acids into peroxisomes of Saccharomyces cerevisiae. EMBO 15:3813-3822.
57. Hodes ME, Pratt VM, Dlouhy SR. 1993. Genetics ot Pelizaeus-Merzbacher disease. Dev Neurosci 15:383-394.
58. Hodes ME, DeMyer WE, Pratt VM, et al. 1995. Girl with signs of Pelizaeus-Merzbacher disease heterozygous for a mutation in exon 2 of proteolipid protein gene. Am J Med Genet 55:397-401.
59. Hohenschutz C, Eich P, Friedl W, et al. 1989. Pseudodeficiency of arylsulfatase A: a common genetic polymorphism with possible disease implications. Hum Genet 82:45-48.
60. Iannetti P, Marciani MG, Spalice A. 1996. Primary CNS demyelinating diseases in childhood: multiple sclerosis. Childs Nerv Syst 12:149-154.
61. Kaul RK, Casanova J, Johnson A, et al. 1991. Purification, characterization and localization of aspartocyclase from bovine brain. J Neurochem 56:129-135.
62. Kaul R, Balmurugan K, Gao GP, et al. 1994. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Genomics 21:364-370.
63. Kemp S, Ligtenberg MJ, van Geel BM, et al. 1994. Identification of a two base pair deletion in five unrelated families with adrenoleukodystrophy: a possible hot spot for mutations. Biochem Biophys Res Comrnun 202:647-653.
64. Kendall BE. 1992. Disorders of lysosomes, peroxisomes and mitochondria. Am J Neuroradiol 13:621-653.
65. Kim TS, Kim I-O, Kim WS, et al. 1997. MR of childhood metachromatic leukodystrophy. Am J Neuroradiol 18:733-738.
66. Knapp PE. 1996. Proteolipid protein: is it more than just a structural component of myelin? Develop Neurosci 18:297-308.
67. Kolodny EH, Raghavan S, Krivit W. 1991. Late onset Krabbe disease (Globoid Cell Leukodystrophy): clinical and biochemical features of 15 cases. Develop Neurosci 13:232-239.
68. Kolodny EH, Fluharty AL. 1995. Metachromatic leukodystrophy and multiple sulfatase deficiency: sulfatide lipidosis. In: Scriver CS, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. McGraw-Hill, p 2693-2739.
69. Korenke GC, Fuchs S, Krasemann E, et al. 1996. Cerebral adrenoleukodystrophy in only one ot monozygotic twins with an identical ALD genotype. Ann Neurol 40:254-257.
70. Kristjansdottir R, Uvebrant P, Hagberg B, et al. 1996. Disorders of the cerebral white matter in children. The spectrum of lesions. Neuropediatr 27:295-298.
71. Krivit W, Lockman LA, Watkins PA, et al. 1995. The future tor treatment by bone marrow transplantation tor adrenoleukodystrophy, metachromatic leukodystrophy and Hurler syndrome. J Inherit Mctab Dis 18:398-412.
72. Kumar AJ, Kohler W, Kruse B, et al. 1995. MR findings in adult-onset adrenoleukodystrophy. AJNR Am J Neuroradiol 16:1227-1237.
73. Leinekugel P, Michel S, Conzelmann E, et al. 1992. Quantitative correlation between the residual activity of b-hexosiminidase A and arylosulphatase A and the severity of the resulting lysosomal storage diseases. Hum Genet 88:513-523.
74. Lemke G. 1992. Myelin and myelination. In: Hall Z, editor. An introduction to molecular neurobiology. Massachusetts: Sinauer, p 281-309.
75. Lemke, G. 1993. The molecular genetics of myelination: an update. Glia 7:263-271.
76. Lemke, G. 1996. Unwrapping myelin. Nature 383: 395-396.
77. Leviton A, Gilles F. 1996. Ventriculomegaly, delayed myelination, white matter hypoplasia, and "periventricular" leukomalacia: how are they related? Pediatr Neurol 15:127-136.
78. Luchinetti CF, Kiers L, O'Duffy A, et al. 1997. Risk factors tor developing multiple sclerosis after childhood optic neuritis. Neurology 49: 1413-1418.
79. Luskin M, Parnaveias J, Barfield J. 1993. Neurons, astrocytes and oligodendrocytes of the rat cerebral cortex originate from separate progenitor cells. J Neurosci 13:1730-1750.
80. Lyon G, Hagberg B, Evrard P, et al. 1991. Symptomatology ot late onset Krabbe's leukodystrophy: the European experience. Develop Neurosci 13:240-244.
81. Malm G, Ringden O, Winiarski J, et al. 1996. Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation. Bone Marrow Transplant 17:1003-1008.
82. Marshal E. 1996. New Zealand's leap into gene therapy. Science 271:1489-1490.
83. Martenson RE. 1992. Myelin: biology and chemistry. Boca Raton, Florida CRC Press, p 1-958.
84. Matalon R, Kaul R, Cassanova J, et al. 1989. Aspartocyclase deficiency: the enzyme defect in Canavan disease. J Inher Metab 12:329-331.
85. Matalon R, Michaels K, Kaul R. 1995. Canavan disease: from spongy degeneration to molecular analysis. J Pediatr 127:511-517.
86. Menegoz M, Gaspar P, LeBert M, et al. 1997. Paranodin, a glycoprotein ot neuronal paranodal membrane. Neuron 19:319-331.
87. Mi H, Deernick T, Ellisman M, et al. 1995. Differential distribution of closely related potassium channels in rat Schwann cells. J Neurosci 15:3761-3774.
88. Miller R. 1996. Oligodendrocyte origin. Trends Neurosci 19:92-96.
89. Millet V, Bartoli JM, Lacroze V, et al. 1998. Predictive significance of magnetic resonance imaging at 4 months ot adjusted age in infants after perinatal neurologic insults. Biol Neonate 73:207-219.
90. Morrell P, Quarles R. 1998. Myelin formation, structure and biochemistry. In: Siegel G, Agranoff B, Albers W, et al., editors. Basic Neurochenustry. Lippincott-Raven. p 69-93.
91. Moser HW, Paliante SL, Moser AB, et al. 1983. Bone marrow transplant in adrenoleukodystrophy. Neurology 34:1410-1417.
92. Moser HW. 1995. Adrenoleukodystrophy: natural history, treatment and outcome. J Inher Metab Dis 18:435-447.
93. Moser HW, Smith KD, Moser AB. 1995. X-linked adrenoleukodystrophy. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. McGraw-Hill. p 2325-2349.
94. Moser HW. 1997. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 120:1485-1508.
95. Moser AB, Kreiter N, Bezman L, et al. 1999a. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 45:100-110.
96. Moser HW, Kemp S, Smith KD. 1999b. Mutational analysis and the pathogenesis of variant X-linked adrenoleukodystrophy phenotypes. Arch Neurol 56:273-275.
97. Mosser J, Lutz Y, Stoeckel ME, et al. 1994. The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet 3:265-271.
98. Natsume J, Watanabe K, Maeda N, et al. 1996. Cortical hypometabolism and delayed myelination in West syndrome. Epilepsia 37:1180-1184.
99. Nave K-A. 1996. Myelin specific genes and their mutations in the mouse. In: Jessen K, Richardson W, editors. Glial cell development. Bios Scientific Publishers. p 141-164.
100. Nishiyama A, Lin X-H, Giese N, et al. 1996. Colocalization between NG2 proteoglycan and PDGFα receptor on O2A progenitor cells in the developing brain. J Neurosci Res 43:299-314.
101. Nowaczyk MJM. Saunders EF, Tein I, et al. Immunoablation does not delay the neurologic progression ot X-linked adrenoleukodystrophy. J Pediatr 1997;131:453-455.
102. Ory-Lavollee L, Blakely KD, Coyle JT. 1987. Neurochemical and immunocytochemical studies on the distribution of N-acetyl-aspartylglutamate and N-acetyl-aspartate in rat spinal cord and some peripheral nervous tissues. J Neurochem 48:895-899.
103. Percy AK, Odrezin GT, Knowels PD, et al. 1994. Globoid cell leukodystrophy: comparison of neuropathology with magnetic resonance imaging. Acta Neuropathol 88:26-32.
104. Pfeiffer S, Warrington A, Bansal R. 1993. The oligodendrocyte and its many cellular processes. Trends in Cell Biol 3:191-197.
105. Poser CM, Paty DW, Scheinberg L, et al. 1983. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231.
106. Powers JM, Liu Y, Moser AB, et al. 1992. The inflammatory myelinopathy ot dreno-leukodystrophy: Cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 51:630-643.
107. Rasmussen M, Moser AB, Borel J, et al. 1994. Brain, liver and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil). Neurochem Res 19:1073-1082.
108. Richardson W, Pringle N, Yu W-U, et al. 1996. Origins and early development of oligodendrocytes. In Jessen K, Richardson W, editors. Glial cell development. Bios Scientific Publishers, p 53-70.
109. Rodriguez M, Siva A, Cross SA, et al. 1995. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 45:244-250.
110. Rudick RA, Cohen JA, Weinstock-Guttman B, et al. 1997. Management of multiple sclerosis. N Engl J Med 337:1604-1611.
111. Ruggieri M, Tigano G, Mazzone D, et al. 1996. Involvement of the white matter in hypomelanosis of Ito (incontinentia pigmenti achromiens). Neurology 46:485-492.
112. Sargent P. 1992. Electrical signaling. In: Hall Z, editor. An introduction to molecular neurobiology. Massachusetts: Sinauer. p 33-80.
113. Saugier-Veber P, Munnich A, Bonneau D, et al. 1994. X-linked spastic paraplegia and Pelizaeus-Merzbacher disease are allelic disorders at the proteolipid protein locus. Nature Genetics 6:257-261.
114. Scherer S. 1996. Molecular specialization at the nodes and paranodes in peripheral nerve. Micros Res Tech 34:452-461.
115. Scherer S, Salzer J. 1996. Axon-Schwann cell interaction during peripheral nerve degeneration and regeneration. In: Jessen K, Richardson W, editors. Glial cell development. Bios Scientific Publishers, p 165-196.
116. Scherer S. 1997. Molecular genetics of demyelination. Neuron 18:13-16.
117. Schlote W, Harzer K, Christomanou H, et al. 1991. Sphingolipid activator protein 1 deficiency in metachromatic leukodystrophy with normal arylsulfatase A activity. A clinical, morphological, biochemical and immunological study. Eur J Pediatr 150:584-591.
118. Schwartz JH. 1991. The cytology of neurons. In: Kandel ER, Schwartz JH, Jessel TM, editors. Principles of neural science. Norwalk: Appleton and Lange. p 37-48.
119. Selmaj K, Raine CS, Canella B, et al. 1991. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87:949-954.
120. Shaag A, Anikster Y, Christensen E, et al. 1995. The molecular basis of Canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am J Hum Genet 57:572-580.
121. Shah NM, Marchionni MA, Issacas I, et al. 1994. Glial growth factor restricts mammalian neural crest stem cells to a glial fate. Cell 77:349-360.
122. Sindern E, Haas J, Stark E, et al. 1992. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol Scand 86:280-284.
123. Singh I, Moser AE, Goldfischer S, et al. 1984. Lignoceric acid is oxidized in the peroxisome: implications for Zellweger cerebro-hepatorenal syndrome and adrenoleukodystrophy. Proc Nad Acad Sci USA 81:4203-4207.
124. Singh I, Khan M, Lyndon P, et al. 1998. Lovastatin for X-linked adrenoleukodystrophy. N Engl J Med 339:702-703.
125. Sistermans EA, de Coo RFM, De Wijs IJ, et al. 1998. Duplication of the proteolipid protein gene is the major cause of Pelizaeus-Merzbacher disease. Neurology 50:1749-1754.
126. Skranes JS, Nilsen G, Smevic O, et al. 1998. Cerebral MRI of very low birth weight children at 6 years of age compared with the findings at 1 year. Pediatr Radiol 28:471-475.
127. Staugaitis S, Smith P, Colman D. 1990. Expression of myelin basic protein isoforms in nonglial cells. J Cell Biol 110:1719-1727.
128. Stewart H, Miesky R, Jessen K. 1996. The Schwann cell lineage: embryonic and early postnatal development. In: Jessen K, Richardson W. editors. Glial cell development. Bios Scientific Publishers, p 1-30.
129. Stumpf DA, Hayward A, Haas R, et al. 1981. Failure ot immunosuppression to prevent neurological progression. Arch Neurol 38:48-19.
130. Suter U, Snipes J. 1995. Peripheral myelin protein-22: Facts and hypotheses. J Neurosci Res 40:145-151.
131. Suzuki K, Suzuki Y, Suzuki K. 1995. Galactosylceramide lipidosis: globoid cell leukodystrophy (Krabbe disease). In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic basis of inherited disease. McGraw-Hill. p 2671-2692.
132. Suzuki K. 1998. Twenty-five years of the "Psychosine Hypothesis": a personal perspective of its history and present status. Biochem Res 23: 251-259.
133. Timsit S, Martinez S, Allinquant B, et al. 1995. Oligodendrocytes originate in a restricted zone of the embryonic ventral neural tube defined by DM20 mRNA expression. J Neurosci 15:1012-1024.
134. Toda K-I, Kobyashi T, Goto I, et al. 1990. Lysosulfatide (sulfogalactosylsphingosine) accumulation in tissues trom patients with metachromatic leukodystrophy. J Neurochem 55:1585-1591.
135. Traeger EC, Rapin I. 1998. The clinical course of Canavan disease. Pediatr Neurol 18:207-212.
136. Tylki-Szymanska A, Czartoryska B, Lugowska A. 1998. Practical suggestions in diagnosing metachromatic leukodystrophy in probands and in testing family members. Eur Neurol 40:67-70.
137. Van der Knaap MS, Valk MJ. 1989. The reflection of histology in MR imaging of Pelizaeus-Merzbacher disease. Am J Neuroradiol 10: 99-103.
138. Van Geel BM, Assies J, Weverling GJ, et al. 1994. Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in the Netherlands: a survey of 30 kindreds. Neurology 44:2343-2346.
139. Vartanian T, Goodearl A, Viehover A, et al. 1997. Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3. J Cell Biol 137:211-220.
140. Watkins PA, Gould SJ, Smith MA, et al. 1995. Altered expression of ALDP in X-linked adrenoleukodystrophy. Am J Hum Genet 57: 292-301.
141. Waxman S. 1996. Pathophysiology of demyelinated and remyelinated axons In: Cook S, editor. Handbook of multiple sclerosis, p 257-294.
142. Weinshenker BG, Bass B, Rice GPA, et al. 1989. The natural history of multiple sclerosis: a geographically based study. Brain 112:133-146.
143. Wenger DA, Rafi MA, Luzi P. 1997. Molecular genetics of Krabbe disease (Globoid cell leukodystrophy): diagnostic and clinical implications. Hum Mut 10:268-279.
144. Williams R, Rigby AS, Airey M, et al. 1995. Multiple sclerosis: its epidemiological, genetic, and health care impact. J Epidimiol Community Health 49:563-569.
145. Zlotogora J, Chakraborty S, Knowlton RG, et al. 1990. Krabbe disease locus mapped to chromosome 14 by genetic linkage. Am J Hum Genet 47:37-44.